Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial

Tricou, Vianney; Yu, Delia; Reynales, Humberto; Biswal, Shibadas; Sáez‐Llorens, Xavier; Sirivichayakul, Chukiat; López, Pío; Borja-Tabora, Charissa; Bravo, Lulu; Kosalaraksa, Pope; Martinez Vargas, Luis; Theresa Alera, Maria; Rivera, Luis; Watanaveeradej, Veerachai; Dietze, Reynaldo; Fernando, LakKumar; Wickramasinghe, Pujitha; Duarte Moreira, Edson; D. Fernando, Asvini; Gunasekera, Dulanie; Giovanni Luz, Kléber; Oliveira, Ana; Tuboi, Suely; Escudero, Ian; Hutagalung, Yanee; Lloyd, Eric; Rauscher, Martina; Zent, Olaf; Folschweiller, Nicolas; Lefevre, Inge; Espinoza, Félix; Wallace, Derek

doi:10.1016/s2214-109x(23)00522-3

Public

Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial

Published in The Lancet Global Health • Jan 21, 2024

Authors:

Vianney Tricou

Delia Yu

Humberto Reynales

Abstract

BACKGROUND: About half of the world's population lives in dengue-endemic areas. We aimed to evaluate the long-term efficacy and safety of two doses of the tetravalent dengue vaccine TAK-003 in preventing symptomatic dengue disease of any severity and due to any dengue virus (DENV) serotypes in child...

Subject

Medicine

Dengue fever

Dengue vaccine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!